Gene: Epo (erythropoietin) Rattus norvegicus
Analyze
Symbol:
Epo
Name:
erythropoietin
Description:
Predicted to have cytokine activity; erythropoietin receptor binding activity; and protein kinase activator activity. Involved in several processes, including positive regulation of ERK1 and ERK2 cascade; positive regulation of activated T cell proliferation; and response to dexamethasone. Localizes to the cell body and extracellular space. Used to study retinal detachment and visual epilepsy. Biomarker of cholangiocarcinoma; eye disease (multiple); transient cerebral ischemia; and vascular dementia. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); diabetic angiopathy; familial erythrocytosis 5; ischemia (multiple); and neurodegenerative disease (multiple). Orthologous to human EPO (erythropoietin); PARTICIPATES IN erythropoietin signaling pathway; hypoxia inducible factor pathway; cytokine mediated signaling pathway; INTERACTS WITH (+)-pilocarpine; 1H-indole; 3',5'-cyclic AMP.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
EPO (erythropoietin) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Mus musculus (house mouse):
Epo (erythropoietin) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, PhylomeDB, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Epo (erythropoietin) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
EPO (erythropoietin) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
EPO (erythropoietin) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Epo (erythropoietin) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
EPO (erythropoietin) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Alliance orthologs 3
Mus musculus (house mouse):
Epo (erythropoietin)
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Homo sapiens (human):
EPO (erythropoietin)
Alliance
DIOPT (Ensembl Compara, HGNC, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Danio rerio (zebrafish):
epoa (erythropoietin a)
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Danio rerio (zebrafish):
epob (erythropoietin b)
Alliance
DIOPT (Ensembl Compara, OMA, OrthoFinder, PANTHER)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 12 22,274,828 - 22,278,268 (+) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 12 22,274,828 - 22,278,266 (+) Ensembl Rnor_5.0 12 24,291,481 - 24,294,921 (+) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 12 19,551,768 - 19,555,208 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 12 19,541,291 - 19,544,730 (-) NCBI Celera 12 21,009,353 - 21,012,793 (+) NCBI Celera Cytogenetic Map 12 q12 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Disease Annotations
RGD Manual Annotations
acute kidney failure treatment ISO RGD:735849 11041660 ; 10400913 RGD Acute-Phase Reaction IEP 10395370 mRNA, protein:increased expression:multiple RGD AIDS Dementia Complex treatment ISO RGD:735849 10395393 RGD Albuminuria ISO RGD:735849 2313841 associated with Diabetes Mellitus, Non-Insulin-Dependent more ... RGD Alzheimer's disease treatment ISO RGD:735849 10400882 ; 10395389 RGD amyotrophic lateral sclerosis disease_progression ISO RGD:735849 10395391 protein:decreased expression:cerebrospinal fluid RGD Anastomotic Leak treatment ISO RGD:735849 10400902 RGD anemia ISO RGD:735849 2313896 associated with Diabetes Mellitus, Non-Insulin-Dependent, protein:increased expression:serum RGD anemia ISO RGD:735849 2313843 associated with Diabetic Nephropathies, protein:decreased expression:serum RGD Brain Hypoxia treatment ISO RGD:735849 10400899 RGD Brain Hypoxia treatment ISO RGD:735849 10401067 associated with Brain Injuries RGD Brain Injuries IEP 2293059 mRNA:increased expression:brain: RGD Brain Injuries treatment ISO RGD:735849 10401061 RGD breast cancer ISO RGD:735849 11041669 protein:increased expression:breast: RGD cholangiocarcinoma IEP 10400912 mRNA, protein:increased expression:liver RGD congestive heart failure treatment ISO RGD:735849 10401073 associated with Myocardial Infarction RGD Diabetes Mellitus, Experimental IEP 11041670 mRNA:increased expression:Schwann cell: RGD Diabetic Nephropathies ISO RGD:735849 2313832 RGD Diabetic Nephropathies ISO RGD:735849 2313833 associated with Diabetes Mellitus, Experimental RGD Diabetic Nephropathies ISO RGD:735849 2313838 DNA:snp:promoter:-1125T>G(rs1617640)(human) RGD diabetic neuropathy ISO RGD:735849 2313898 associated with Diabetes Mellitus, Experimental RGD diabetic retinopathy ISO RGD:735849 2313890 associated with Diabetes Mellitus, Experimental RGD diabetic retinopathy susceptibility ISO RGD:735849 10400906 associated with Diabetes Mellitus, Experimental RGD diabetic retinopathy ISO RGD:735849 2313837 protein:increased expression:serum, vitreous body RGD diabetic retinopathy ISO RGD:735849 2313838 DNA:snp:promoter:-1125T>G(rs1617640)(human) RGD Endotoxemia treatment ISO RGD:735849 10400903 RGD Experimental Autoimmune Neuritis IEP 10400894 RGD Fetal Distress IEP 10401064 mRNA, protein:increased expression:brain, serum RGD glaucoma IEP 11041649 protein:increased expression:retina: RGD glaucoma ISO RGD:735849 10401071 ; 11041649 RGD Hematoma, Subdural, Acute treatment ISO RGD:735849 10401075 RGD Hemorrhagic Shock treatment ISO RGD:735849 10401059 RGD hypoglycemia ISO RGD:735849 2313835 associated with Diabetes Mellitus, Insulin-Dependent, protein:increased expression:plasma RGD Hypoxia-Ischemia, Brain treatment ISO RGD:735849 10401072 RGD Hypoxia-Ischemia, Brain IEP 10400911 RGD Kidney Reperfusion Injury treatment ISO RGD:735849 11041698 ; 10401077 RGD Knee Osteoarthritis treatment ISO RGD:735849 10400892 RGD Limb Ischemia treatment ISO RGD:735849 10400895 RGD macular retinal edema severity ISO RGD:735849 10400883 RGD malignant glioma ISO RGD:735849 10400910 RGD Mammary Neoplasms, Experimental treatment IMP 11041669 RGD middle cerebral artery infarction treatment ISO RGD:735849 10401066 ; 10400898 RGD myocardial infarction treatment ISO RGD:735849 10400907 RGD Necrosis treatment ISO RGD:735849 8655615 associated with Ischemia RGD nephrotic syndrome treatment ISO RGD:735849 11041725 RGD neurodegenerative disease susceptibility ISO RGD:735849 10400893 associated with Brain Injuries RGD Parkinson's disease treatment ISO RGD:735849 10400901 RGD placental insufficiency treatment ISO RGD:735849 10400897 RGD porphyria ISO RGD:735849 2313839 associated with Diabetes Mellitus, nephrosclerosis RGD Pregnancy Complications ISO RGD:735849 2313897 associated with Pregnancy in Diabetes, protein:increased expression:amniotic fluid RGD pulmonary hypertension treatment ISO RGD:735849 10400914 RGD retinal degeneration treatment ISO RGD:10531 10400896 RGD retinal detachment IEP 11041648 mRNA, protein:increased expression:retina: RGD retinal detachment treatment IDA 10401069 RGD retinopathy of prematurity IEP 11041658 protein:decreased expression:retina: RGD severe combined immunodeficiency ISO RGD:10531 2313831 Protein: decreased expression:skin RGD Spinal Cord Compression IEP 11041719 protein:increased expression:neuron, endothelium, glia: RGD Spinal Cord Injuries treatment ISO RGD:735849 10401074 RGD Subarachnoid Hemorrhage treatment ISO RGD:735849 10400909 RGD transient cerebral ischemia treatment ISO RGD:735849 11041699 RGD transient cerebral ischemia treatment IEP 10401060 RGD Tubulointerstitial Fibrosis treatment ISO RGD:735849 10401065 RGD type 2 diabetes mellitus ISO RGD:735849 2313842 protein:decreased expression:plasma RGD type 2 diabetes mellitus ISO RGD:735849 2313840 mRNA:increased expression:retina RGD vascular dementia IEP 10400891 RGD visual epilepsy treatment IDA 10401076 RGD Wounds, Penetrating treatment ISO RGD:735849 10401063 associated with Diabetes Mellitus, Experimental RGD
Imported Annotations - ClinVar
diabetic angiopathy ISO RGD:735849 8554872 ClinVar Annotator: match by OMIM:612623 ClinVar PMID:18458324 DIAMOND-BLACKFAN ANEMIA-LIKE ISO RGD:735849 8554872 ClinVar Annotator: match by term: DIAMOND-BLACKFAN ANEMIA-LIKE ClinVar PMID:28283061 familial erythrocytosis 5 ISO RGD:735849 8554872 ClinVar Annotator: match by term: ERYTHROCYTOSIS, FAMILIAL, 5 ClinVar PMID:29514032 familial erythrocytosis 5 ISO RGD:735849 8554872 ClinVar Annotator: match by term: ERYTHROCYTOSIS, FAMILIAL, 5 ClinVar PMID:27651169 , PMID:29514032 pleomorphic xanthoastrocytoma ISO RGD:735849 8554872 ClinVar Annotator: match by term: Pleomorphic xanthoastrocytoma ClinVar PMID:28299358
Imported Annotations - CTD
acute kidney failure ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:21847101 , PMID:24561306 anemia ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism, therapeutic CTD PMID:1516988 more ... beta thalassemia ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:16225658 Brain Injuries ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:20833152 calcinosis ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:12148126 Cardiogenic Shock ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19337937 cardiomyopathy ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:16449733 more ... central nervous system disease ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:15816862 cognitive disorder ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:20833152 congenital diaphragmatic hernia ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:27880037 coronary artery disease ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:25245553 end stage renal failure ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:16707910 Experimental Autoimmune Encephalomyelitis ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:18382691 Experimental Sarcoma ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:9743294 Fatigue ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:18695134 gastric ulcer ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:20723003 heart disease ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:16707910 hemolytic anemia ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:10733367 more ... hemolytic-uremic syndrome ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:12053072 hypertension ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:1516988 , PMID:10694834 Inflammation ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:21497595 kidney disease ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:20606417 kidney failure ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:22013135 melanoma ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:15743794 Micronuclei, Chromosome-Defective ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:30944280 myelodysplastic syndrome ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:12670338 , PMID:16076383 myocardial infarction ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19337937 Neoplasm Invasiveness ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:16699298 Neoplasm Metastasis ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:16699298 Nerve Degeneration ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:17010629 more ... neurodegenerative disease ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:15816862 pancytopenia ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:9051142 Paraneoplastic Syndromes ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:10713657 Poisoning ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:15727166 polyneuropathy ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:17010629 pulmonary embolism ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:12670338 status epilepticus ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:16679645 , PMID:17166730 thrombocytopenia ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:8260696 thrombosis ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:14979412 , PMID:25013951 Thyroid Neoplasms ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:16699298 uremia ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:12675867 vascular disease ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:25013951 Venous Thrombosis ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:12670338 , PMID:17547733 Ventricular Fibrillation ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:18156309 ventricular septal defect ISO RGD:735849 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19337937 Ventricular Tachycardia ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:18156309 Weight Loss ISO RGD:735849 11554173 CTD Direct Evidence: therapeutic CTD PMID:8260696 Imported Annotations - OMIM
diabetic angiopathy ISO RGD:735849 7240710 OMIM DIAMOND-BLACKFAN ANEMIA-LIKE ISO RGD:735849 7240710 OMIM familial erythrocytosis 5 ISO RGD:735849 7240710 OMIM
(+)-pilocarpine increases expression EXP 6480464 Pilocarpine results in increased expression of EPO mRNA CTD PMID:17166730 (R)-noradrenaline decreases response to substance ISO RGD:10531 6480464 EPO protein results in decreased susceptibility to Norepinephrine CTD PMID:14732207 (S)-nicotine increases expression ISO RGD:735849 6480464 Nicotine results in increased expression of EPO mRNA CTD PMID:18247414 1-octadec-9-enoylglycero-3-phosphate multiple interactions ISO RGD:735849 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] more ... CTD PMID:21915944 1H-indole multiple interactions EXP 6480464 indole inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA], indole inhibits the reaction [cobaltous chloride results in increased expression of EPO protein] CTD PMID:21863063 2-hydroxypropanoic acid decreases expression ISO RGD:735849 6480464 Lactic Acid results in decreased expression of EPO mRNA CTD PMID:30851411 2-naphthylamine increases expression ISO RGD:735849 6480464 2-Naphthylamine results in increased expression of EPO mRNA CTD PMID:18247414 3',5'-cyclic AMP increases expression EXP 6480464 Cyclic AMP results in increased expression of EPO protein CTD PMID:18621143 3',5'-cyclic GMP multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP], EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] CTD PMID:25041251 , PMID:25490417 5,6,7,8-tetrahydrobiopterin multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ... CTD PMID:25041251 , PMID:25490417 5,6,7,8-tetrahydrobiopterin multiple interactions ISO RGD:735849 6480464 EPO protein inhibits the reaction [GCH1 mutant form results in decreased abundance of sapropterin] CTD PMID:25041251 5,6,7,8-tetrahydrobiopterin increases abundance ISO RGD:10531 6480464 EPO protein results in increased abundance of sapropterin CTD PMID:25490417 5-aza-2'-deoxycytidine increases expression ISO RGD:735849 6480464 Decitabine results in increased expression of EPO mRNA CTD PMID:19194470 5-chloro-7-iodoquinolin-8-ol increases expression ISO RGD:735849 6480464 Clioquinol results in increased expression of EPO mRNA CTD PMID:16973622 5-chloro-7-iodoquinolin-8-ol decreases expression ISO RGD:735849 6480464 Clioquinol results in decreased expression of EPO mRNA CTD PMID:19502547 5-fluorouracil increases response to substance ISO RGD:735849 6480464 EPO protein results in increased susceptibility to Fluorouracil CTD PMID:16103069 5-fluorouracil increases expression EXP 6480464 Fluorouracil results in increased expression of EPO protein CTD PMID:20020992 , PMID:2206997 7,12-dimethyltetraphene decreases expression ISO RGD:735849 6480464 9 more ... CTD PMID:19502547 acetylcholine multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [GCH1 gene mutant form results in decreased susceptibility to Acetylcholine] CTD PMID:25490417 acetylcholine increases response to substance ISO RGD:10531 6480464 EPO protein results in increased susceptibility to Acetylcholine CTD PMID:25490417 Actein decreases expression EXP 6480464 actein results in decreased expression of EPO mRNA CTD PMID:19527300 aflatoxin B1 decreases expression ISO RGD:735849 6480464 Aflatoxin B1 results in decreased expression of EPO mRNA CTD PMID:21641981 , PMID:22100608 aldehydo-D-glucose multiple interactions ISO RGD:735849 6480464 [EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA more ... CTD PMID:30894315 all-trans-retinoic acid increases expression EXP 6480464 Tretinoin results in increased expression of EPO mRNA CTD PMID:20488242 all-trans-retinol increases expression ISO RGD:735849 6480464 Vitamin A results in increased expression of EPO protein CTD PMID:16960172 all-trans-retinol increases expression EXP 6480464 Vitamin A results in increased expression of EPO protein CTD PMID:9927288 all-trans-retinol multiple interactions EXP 6480464 Vitamin A inhibits the reaction [Hydrogen Peroxide results in decreased expression of EPO protein] CTD PMID:9927288 amitrole multiple interactions ISO RGD:735849 6480464 [Amitrole results in increased abundance of Hydrogen Peroxide] which results in decreased expression of EPO protein CTD PMID:7980410 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of EPO mRNA CTD PMID:16483693 amphotericin B multiple interactions ISO RGD:735849 6480464 Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer], Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:16189267 amphotericin B decreases expression ISO RGD:735849 6480464 Amphotericin B results in decreased expression of EPO protein CTD PMID:2299214 , PMID:697352 amphotericin B multiple interactions EXP 6480464 Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:16189267 benzene multiple interactions ISO RGD:10531 6480464 Benzene inhibits the reaction [Formaldehyde results in increased expression of EPO mRNA] CTD PMID:28373009 benzo[a]pyrene increases expression ISO RGD:735849 6480464 Benzo(a)pyrene results in increased expression of EPO mRNA CTD PMID:18247414 benzo[a]pyrene decreases expression ISO RGD:735849 6480464 Benzo(a)pyrene results in decreased expression of EPO mRNA CTD PMID:22316170 bisphenol A multiple interactions ISO RGD:735849 6480464 bisphenol A inhibits the reaction [Cobalt results in increased expression of EPO mRNA], bisphenol A inhibits the reaction [HIF1A protein results in increased expression of EPO mRNA] CTD PMID:15147973 bisphenol A affects expression ISO RGD:735849 6480464 bisphenol A affects the expression of EPO mRNA CTD PMID:30903817 BQ 123 multiple interactions EXP 6480464 cyclo(Trp-Asp-Pro-Val-Leu) promotes the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:24557580 cadmium atom multiple interactions ISO RGD:735849 6480464 Cadmium inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EPO promoter]], Cadmium inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:10866824 cadmium dichloride decreases expression EXP 6480464 Cadmium Chloride results in decreased expression of EPO protein CTD PMID:21540277 cadmium dichloride multiple interactions ISO RGD:735849 6480464 Cadmium Chloride inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA] more ... CTD PMID:11090055 cadmium dichloride decreases methylation EXP 6480464 Cadmium Chloride results in decreased methylation of EPO promoter CTD PMID:22457795 calycosin increases expression ISO RGD:735849 6480464 7, 3'-dihydroxy-4'-methoxyisoflavone results in increased expression of EPO mRNA CTD PMID:21309574 calycosin-7-O-beta-D-glucoside increases expression ISO RGD:735849 6480464 calycosin-7-O-beta-D-glucoside results in increased expression of EPO mRNA CTD PMID:21309574 carbamazepine affects expression ISO RGD:735849 6480464 Carbamazepine affects the expression of EPO mRNA CTD PMID:24752500 carbon monoxide increases expression EXP 6480464 Carbon Monoxide results in increased expression of EPO mRNA, Carbon Monoxide results in increased expression of EPO protein CTD PMID:9263988 carboplatin increases expression EXP 6480464 Carboplatin results in increased expression of EPO protein CTD PMID:17891399 cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of EPO protein CTD PMID:2206997 cisplatin increases response to substance ISO RGD:735849 6480464 EPO protein results in increased susceptibility to Cisplatin CTD PMID:23077460 cisplatin decreases response to substance ISO RGD:735849 6480464 EPO protein results in decreased susceptibility to Cisplatin CTD PMID:23077460 cisplatin multiple interactions ISO RGD:735849 6480464 Cisplatin inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA] more ... CTD PMID:11090055 , PMID:22013135 cisplatin affects expression EXP 6480464 Cisplatin affects the expression of EPO protein CTD PMID:20020992 cisplatin decreases response to substance EXP 6480464 EPO protein results in decreased susceptibility to Cisplatin CTD PMID:20722073 cobalt atom multiple interactions ISO RGD:735849 6480464 bisphenol A inhibits the reaction [Cobalt results in increased expression of EPO mRNA] CTD PMID:15147973 cobalt atom increases expression EXP 6480464 Cobalt results in increased expression of EPO mRNA, Cobalt results in increased expression of EPO protein CTD PMID:17967803 , PMID:23877121 cobalt atom multiple interactions EXP 6480464 Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO mRNA], Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO protein] CTD PMID:23877121 cobalt atom increases expression ISO RGD:735849 6480464 Cobalt results in increased expression of EPO mRNA CTD PMID:10699462 more ... cobalt dichloride multiple interactions ISO RGD:735849 6480464 Cadmium Chloride inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA] more ... CTD PMID:11090055 more ... cobalt dichloride increases expression ISO RGD:10531 6480464 cobaltous chloride results in increased expression of EPO mRNA, cobaltous chloride results in increased expression of EPO protein CTD PMID:10756076 , PMID:16772336 cobalt dichloride multiple interactions EXP 6480464 [cobaltous chloride results in increased expression of and results in increased activity of HIF1A protein] which results in increased expression of EPO protein more ... CTD PMID:18331222 more ... cobalt dichloride affects expression ISO RGD:735849 6480464 cobaltous chloride affects the expression of EPO protein CTD PMID:15743794 cobalt dichloride increases expression EXP 6480464 cobaltous chloride deficiency results in increased expression of EPO protein more ... CTD PMID:12819242 more ... cobalt dichloride increases expression ISO RGD:735849 6480464 cobaltous chloride results in increased expression of EPO mRNA, cobaltous chloride results in increased expression of EPO protein CTD PMID:11090055 more ... copper(II) sulfate decreases expression ISO RGD:735849 6480464 Copper Sulfate results in decreased expression of EPO mRNA CTD PMID:19549813 cortisol increases expression ISO RGD:735849 6480464 Hydrocortisone results in increased expression of EPO protein CTD PMID:10694834 curcumin decreases expression ISO RGD:735849 6480464 Curcumin results in decreased expression of EPO mRNA CTD PMID:16880289 cycloheximide multiple interactions ISO RGD:10531 6480464 Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:10756076 cyclophosphamide multiple interactions EXP 6480464 angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA], Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA] CTD PMID:19627214 cyclophosphamide increases response to substance EXP 6480464 EPO protein results in increased susceptibility to Cyclophosphamide CTD PMID:11245434 cyclophosphamide decreases expression EXP 6480464 Cyclophosphamide results in decreased expression of EPO mRNA CTD PMID:19627214 cyclosporin A decreases expression ISO RGD:735849 6480464 Cyclosporine results in decreased expression of EPO mRNA CTD PMID:20106945 , PMID:25562108 cytochalasin B multiple interactions ISO RGD:735849 6480464 [Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein more ... CTD PMID:18776917 D-glucose multiple interactions ISO RGD:735849 6480464 [EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA more ... CTD PMID:30894315 dacarbazine decreases response to substance ISO RGD:735849 6480464 EPO protein results in decreased susceptibility to Dacarbazine CTD PMID:15743794 decabromodiphenyl ether increases expression EXP 6480464 decabromobiphenyl ether results in increased expression of EPO mRNA CTD PMID:23914054 dehydroepiandrosterone multiple interactions ISO RGD:735849 6480464 [Dehydroepiandrosterone co-treated with Testosterone co-treated with GH1] results in decreased expression of EPO protein CTD PMID:15161484 desferrioxamine B increases expression ISO RGD:735849 6480464 Deferoxamine results in increased expression of EPO mRNA CTD PMID:10699462 desferrioxamine B increases expression ISO RGD:10531 6480464 Deferoxamine deficiency results in increased expression of EPO mRNA, Deferoxamine results in increased expression of EPO mRNA CTD PMID:10756076 desferrioxamine B increases stability ISO RGD:10531 6480464 Deferoxamine deficiency results in increased stability of EPO mRNA CTD PMID:10756076 desferrioxamine B increases expression EXP 6480464 Deferoxamine results in increased expression of EPO mRNA, Deferoxamine results in increased expression of EPO protein CTD PMID:10559391 more ... desferrioxamine B multiple interactions EXP 6480464 Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein] CTD PMID:9927288 dexamethasone multiple interactions ISO RGD:735849 6480464 Dexamethasone analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein] CTD PMID:18776917 diclofenac affects expression ISO RGD:735849 6480464 Diclofenac affects the expression of EPO mRNA CTD PMID:24752500 diethylstilbestrol multiple interactions EXP 6480464 Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO mRNA] more ... CTD PMID:23877121 dioxygen multiple interactions ISO RGD:735849 6480464 15 more ... CTD PMID:10866824 more ... dioxygen increases secretion ISO RGD:735849 6480464 Oxygen deficiency results in increased secretion of EPO protein CTD PMID:23958427 dioxygen increases expression ISO RGD:735849 6480464 Oxygen deficiency results in increased expression of EPO mRNA, Oxygen deficiency results in increased expression of EPO protein CTD PMID:10866824 more ... dioxygen increases expression ISO RGD:10531 6480464 Oxygen deficiency results in increased expression of EPO mRNA CTD PMID:10756076 more ... dioxygen multiple interactions ISO RGD:10531 6480464 Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA], Hydrogen Peroxide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:10756076 dioxygen increases expression EXP 6480464 Oxygen deficiency results in increased expression of EPO more ... CTD PMID:18331222 more ... dioxygen multiple interactions EXP 6480464 [Oxygen deficiency co-treated with cobaltous chloride] results in increased expression of EPO mRNA more ... CTD PMID:16189267 more ... doxorubicin multiple interactions ISO RGD:10531 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]] more ... CTD PMID:16449733 , PMID:17928571 doxorubicin increases response to substance EXP 6480464 EPO protein results in increased susceptibility to Doxorubicin CTD PMID:17924179 doxorubicin increases response to substance ISO RGD:10531 6480464 EPO protein results in increased susceptibility to Doxorubicin CTD PMID:17928571 doxorubicin multiple interactions EXP 6480464 EPO protein inhibits the reaction [Doxorubicin results in decreased abundance of Glutathione] more ... CTD PMID:16405037 more ... EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor decreases expression ISO RGD:735849 6480464 Angiotensin-Converting Enzyme Inhibitors results in decreased expression of EPO protein CTD PMID:2474097 enalapril decreases expression ISO RGD:735849 6480464 Enalapril results in decreased expression of EPO protein CTD PMID:2474097 , PMID:9434678 enalapril multiple interactions EXP 6480464 Enalapril inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] CTD PMID:19958114 etoposide multiple interactions ISO RGD:735849 6480464 EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide] CTD PMID:18403296 fenoterol increases expression ISO RGD:735849 6480464 Fenoterol results in increased expression of EPO protein CTD PMID:9209250 formaldehyde multiple interactions ISO RGD:10531 6480464 Benzene inhibits the reaction [Formaldehyde results in increased expression of EPO mRNA] CTD PMID:28373009 formaldehyde increases expression ISO RGD:10531 6480464 Formaldehyde results in increased expression of EPO mRNA CTD PMID:28373009 formononetin increases expression ISO RGD:735849 6480464 formononetin results in increased expression of EPO mRNA CTD PMID:21309574 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of EPO protein CTD PMID:1982298 gentamycin decreases response to substance EXP 6480464 EPO protein results in decreased susceptibility to Gentamicins CTD PMID:16467726 glucose multiple interactions ISO RGD:735849 6480464 [EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA more ... CTD PMID:30894315 glutathione multiple interactions EXP 6480464 EPO protein inhibits the reaction [Doxorubicin results in decreased abundance of Glutathione] CTD PMID:16405037 glutathione multiple interactions ISO RGD:735849 6480464 EPO protein inhibits the reaction [Cisplatin results in decreased abundance of Glutathione] CTD PMID:22013135 haloperidol multiple interactions EXP 6480464 EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein] more ... CTD PMID:17805306 hydrogen peroxide multiple interactions ISO RGD:735849 6480464 [Amitrole results in increased abundance of Hydrogen Peroxide] which results in decreased expression of EPO protein more ... CTD PMID:7980410 hydrogen peroxide multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Hydrogen Peroxide], Hydrogen Peroxide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:10756076 , PMID:25490417 hydrogen peroxide multiple interactions EXP 6480464 Vitamin A inhibits the reaction [Hydrogen Peroxide results in decreased expression of EPO protein] CTD PMID:9927288 hydrogen peroxide decreases expression EXP 6480464 Hydrogen Peroxide results in decreased expression of EPO protein CTD PMID:9927288 hydrogen peroxide decreases expression ISO RGD:735849 6480464 Hydrogen Peroxide results in decreased expression of EPO protein CTD PMID:7980410 hydroxyurea increases expression ISO RGD:735849 6480464 Hydroxyurea results in increased expression of EPO protein CTD PMID:19724057 indometacin multiple interactions EXP 6480464 EPO protein inhibits the reaction [Indomethacin results in increased activity of MPO protein] CTD PMID:20723003 indoxyl sulfate multiple interactions ISO RGD:735849 6480464 Indican inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA], Indican inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:21863063 iron atom affects response to substance ISO RGD:735849 6480464 Iron affects the susceptibility to EPO protein CTD PMID:24806658 iron(0) affects response to substance ISO RGD:735849 6480464 Iron affects the susceptibility to EPO protein CTD PMID:24806658 iron(III) citrate increases expression ISO RGD:735849 6480464 ferric citrate results in increased expression of EPO mRNA CTD PMID:29959986 kainic acid multiple interactions ISO RGD:735849 6480464 EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein] more ... CTD PMID:18711747 ketoconazole multiple interactions ISO RGD:735849 6480464 Ketoconazole inhibits the reaction [CYP3A4 protein promotes the reaction [Oxygen deficiency results in increased expression of EPO mRNA]], Ketoconazole inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:21566342 L-erythro-7,8-dihydrobiopterin multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ... CTD PMID:25041251 , PMID:25490417 lipopolysaccharide multiple interactions ISO RGD:10531 6480464 [Lipopolysaccharides co-treated with EPO protein] results in increased expression of BCL2L1 protein more ... CTD PMID:24561306 LY294002 multiple interactions ISO RGD:735849 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein], 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in increased abundance of Nitrites] CTD PMID:21915944 , PMID:23384249 LY294002 multiple interactions ISO RGD:10531 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]] more ... CTD PMID:17928571 LY294002 multiple interactions EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in decreased susceptibility to Levodopa], 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO results in increased phosphorylation of GSK3B protein] CTD PMID:17952604 , PMID:21683736 malonaldehyde decreases abundance ISO RGD:735849 6480464 EPO protein results in decreased abundance of Malondialdehyde CTD PMID:22013135 manganese atom increases glycosylation ISO RGD:735849 6480464 Manganese results in increased glycosylation of EPO protein CTD PMID:16937399 manganese(0) increases glycosylation ISO RGD:735849 6480464 Manganese results in increased glycosylation of EPO protein CTD PMID:16937399 menadione multiple interactions ISO RGD:735849 6480464 [Vitamin K 3 results in increased abundance of Hydrogen Peroxide] which results in decreased expression of EPO protein CTD PMID:7980410 mercury dichloride multiple interactions ISO RGD:735849 6480464 Mercuric Chloride inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA] more ... CTD PMID:11090055 microcystin-LR decreases expression ISO RGD:10531 6480464 cyanoginosin LR results in decreased expression of EPO mRNA, cyanoginosin LR results in decreased expression of EPO protein CTD PMID:23454832 neopterin multiple interactions ISO RGD:10531 6480464 EPO protein promotes the reaction [GCH1 protein results in increased chemical synthesis of Neopterin] CTD PMID:25490417 nicotine increases expression ISO RGD:735849 6480464 Nicotine results in increased expression of EPO mRNA CTD PMID:18247414 nitric oxide decreases response to substance EXP 6480464 EPO protein results in decreased susceptibility to Nitric Oxide CTD PMID:15816862 nitrites multiple interactions ISO RGD:735849 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in increased abundance of Nitrites] CTD PMID:23384249 nitrites increases abundance ISO RGD:735849 6480464 EPO protein results in increased abundance of Nitrites CTD PMID:23384249 nitrofen decreases expression EXP 6480464 nitrofen results in decreased expression of EPO mRNA, nitrofen results in decreased expression of EPO protein CTD PMID:27880037 nitroprusside multiple interactions ISO RGD:735849 6480464 Nitroprusside inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:11286986 Nonidet P-40 decreases expression ISO RGD:735849 6480464 Nonidet P-40 results in decreased expression of EPO mRNA CTD PMID:26552463 ochratoxin A affects expression ISO RGD:735849 6480464 ochratoxin A affects the expression of EPO mRNA CTD PMID:30876885 ozone increases expression ISO RGD:735849 6480464 Ozone results in increased expression of EPO mRNA CTD PMID:27206323 paclitaxel decreases response to substance ISO RGD:735849 6480464 EPO protein results in decreased susceptibility to Paclitaxel CTD PMID:17010629 paracetamol increases expression ISO RGD:10531 6480464 Acetaminophen results in increased expression of EPO mRNA CTD PMID:22610607 paraquat multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [SOD2 gene mutant form results in increased susceptibility to Paraquat] CTD PMID:16288465 phenobarbital increases expression ISO RGD:10531 6480464 Phenobarbital results in increased expression of EPO mRNA CTD PMID:23528251 phenylhydrazine increases expression EXP 6480464 phenylhydrazine results in increased expression of EPO mRNA CTD PMID:22908232 pirinixic acid multiple interactions ISO RGD:10531 6480464 NCF1 protein promotes the reaction [pirinixic acid results in decreased expression of EPO mRNA] CTD PMID:17950772 pirinixic acid decreases expression ISO RGD:10531 6480464 pirinixic acid results in decreased expression of EPO mRNA CTD PMID:17950772 pyrogallol decreases expression EXP 6480464 Pyrogallol results in decreased expression of EPO protein CTD PMID:9927288 quercetin increases expression ISO RGD:735849 6480464 Quercetin results in increased expression of EPO mRNA CTD PMID:19729006 quercetin decreases expression ISO RGD:735849 6480464 Quercetin results in decreased expression of EPO mRNA CTD PMID:21632981 quercetin multiple interactions ISO RGD:735849 6480464 Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] more ... CTD PMID:21915944 rac-lactic acid decreases expression ISO RGD:735849 6480464 Lactic Acid results in decreased expression of EPO mRNA CTD PMID:30851411 reactive oxygen species multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [Doxorubicin results in increased abundance of Reactive Oxygen Species] CTD PMID:17928571 reactive oxygen species multiple interactions EXP 6480464 Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein], tetramethylthiourea inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein] CTD PMID:9927288 reactive oxygen species decreases abundance ISO RGD:735849 6480464 EPO protein results in decreased abundance of Reactive Oxygen Species CTD PMID:12200812 resveratrol multiple interactions ISO RGD:735849 6480464 resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein], resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein] CTD PMID:18776917 ribavirin multiple interactions ISO RGD:735849 6480464 [peginterferon alfa-2b co-treated with Ribavirin] affects the expression of EPO protein, [Ribavirin co-treated with Interferons] results in increased expression of EPO protein CTD PMID:15232364 , PMID:20009130 ribavirin increases expression ISO RGD:735849 6480464 Ribavirin results in increased expression of EPO CTD PMID:12713065 salubrinal multiple interactions ISO RGD:735849 6480464 [salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein, [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein CTD PMID:23690448 sapropterin increases abundance ISO RGD:10531 6480464 EPO protein results in increased abundance of sapropterin CTD PMID:25490417 sapropterin multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ... CTD PMID:25041251 , PMID:25490417 sapropterin multiple interactions ISO RGD:735849 6480464 EPO protein inhibits the reaction [GCH1 mutant form results in decreased abundance of sapropterin] CTD PMID:25041251 simvastatin multiple interactions EXP 6480464 Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein], Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] CTD PMID:20821229 sodium stibogluconate decreases expression ISO RGD:735849 6480464 Antimony Sodium Gluconate results in decreased expression of EPO mRNA, Antimony Sodium Gluconate results in decreased expression of EPO protein CTD PMID:9531339 staurosporine decreases response to substance EXP 6480464 EPO protein results in decreased susceptibility to Staurosporine CTD PMID:15816862 staurosporine multiple interactions EXP 6480464 tin mesoporphyrin inhibits the reaction [EPO protein results in decreased susceptibility to Staurosporine] CTD PMID:15816862 streptozocin multiple interactions EXP 6480464 Enalapril inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] more ... CTD PMID:19958114 , PMID:20821229 streptozocin increases expression EXP 6480464 Streptozocin results in increased expression of EPO mRNA CTD PMID:19958114 , PMID:20821229 streptozocin decreases expression EXP 6480464 Streptozocin results in decreased expression of EPO protein CTD PMID:20821229 superoxide multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides] CTD PMID:25490417 testosterone multiple interactions ISO RGD:735849 6480464 [Dehydroepiandrosterone co-treated with Testosterone co-treated with GH1] results in decreased expression of EPO protein CTD PMID:15161484 urethane decreases expression ISO RGD:735849 6480464 Urethane results in decreased expression of EPO mRNA CTD PMID:28818685 zidovudine increases expression ISO RGD:735849 6480464 Zidovudine results in increased expression of EPO protein CTD PMID:3422548 zidovudine multiple interactions ISO RGD:10531 6480464 EPO protein inhibits the reaction [Zidovudine results in decreased expression of EPOR mRNA] more ... CTD PMID:7646543 , PMID:9735323 zidovudine increases expression ISO RGD:10531 6480464 Zidovudine results in increased expression of EPO protein CTD PMID:1549625 , PMID:1889487 zinc dichloride multiple interactions ISO RGD:735849 6480464 zinc chloride inhibits the reaction [cobaltous chloride results in increased expression of EPO protein], zinc chloride inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] CTD PMID:11090055
Gene-Chemical Interaction Annotations
